NCT02747342 is a Phase 1 clinical trial of SHR3680; SHR3162 in Neoplasm, sponsored by Atridia Pty Ltd..

Who is sponsoring NCT02747342?

NCT02747342 is sponsored by Atridia Pty Ltd..

What drugs are being tested in NCT02747342?

Interventions in NCT02747342: SHR3680; SHR3162.

What condition does NCT02747342 study?

NCT02747342 studies Neoplasm, Prostate Cancer.

Is NCT02747342 still recruiting?

NCT02747342 is currently completed. Last updated 20 July 2020.

Last reviewed 2020-07-20 · How we verify

NCT02747342

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Phase 1 Trial of SHR3680 With or Without SHR3162 in Subjects With Metastatic Castration-Resistant Prostate Cancer

Completed Phase 1 Last updated 20 July 2020

What this trial tests

Phase 1 trial testing SHR3680; SHR3162 in Neoplasm in 33 participants. Completed in 28 June 2020.

Timeline

1 September 2016

Primary endpoint
28 June 2019

28 June 2020

Quick facts

Lead sponsor	Atridia Pty Ltd.
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	33
Start date	1 September 2016
Primary completion	28 June 2019
Estimated completion	28 June 2020
Sites	6 locations across Australia

Drugs / interventions tested

SHR3680; SHR3162 — full drug profile →

Conditions studied

Neoplasm — all drugs for Neoplasm →
Prostate Cancer — all drugs for Prostate Cancer →

Sponsor

Atridia Pty Ltd. — full company profile →

Who can join

18 and older, male only, with Neoplasm or Prostate Cancer. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Maximum tolerated dose (MTD)
Time frame: 4 weeks
MTD is defined as the maximum dose level at which no more than 1 out of 3 participants experience a DLT within the first 4 weeks of multiple dosing
Recommended Phase 2 doses (RP2Ds)
Time frame: 24 months
RP2D will be determined based on the available data for toxicity and PK.

Sponsor's own description

This is a multicenter, dose-escalation/expansion phase 1 trial to evaluate the safety, tolerability and efficacy of SHR3680 with or without SHR3162 given orally to subjects with metastatic castration-resistant prostate cancer (mCRPC).

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

The androgen receptor-targeted proteolysis targeting chimera and other alternative therapeutic choices in overcoming the resistance to androgen deprivation treatment in prostate cancer.
Li L, Xu J. · · 2023 · cited 5× · PMID 36203075 · DOI 10.1007/s12094-022-02957-x

Verify or expand the search:

Other recruiting trials for Neoplasm

Currently open trials in the same condition.

NCT07447089 — EMDR Integrative Group Protocol and Individual Treatment for Patients With Cancer: A Pilot Study · NA · recruiting
NCT06739655 — Preoperative Radiation Therapy and Immediate Breast Reconstruction · NA · recruiting
NCT06813235 — Dream2Heal: An Adaptive Stepped-care Intervention for Chinese Cancer Survivors With Mild-to-moderate Insomnia · NA · recruiting
NCT06759649 — A Clinical Trial to Assess COM503 in Participants With Advanced Solid Malignancies · Phase 1 · recruiting
NCT06980012 — Evaluation of the Impact of the Clinical Pharmacist in Oral Therapies in Oncology. · NA · recruiting

Other Atridia Pty Ltd. trials

Trials by the same sponsor.

NCT07358377 — To Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of HRS-6209 in Subjects With HR-Positive/HER2-Negati · Phase 1 · not yet recruiting
NCT07390747 — A Trial of SHR-2173 in Healthy Volunteers · Phase 1 · recruiting
NCT07238647 — A Trial of HRS-5817 in Obese Participants · EARLY_PHASE1 · recruiting
NCT07078695 — A Trial of SHR-1139 in Healthy Volunteers · Phase 1 · active not recruiting
NCT07033455 — A Trial of HRS-1893 in Healthy Volunteers · EARLY_PHASE1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02747342 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Atridia Pty Ltd.
Last refreshed: 20 July 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02747342.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing